Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hit a lot of stop losses and panic selling.
Yeah
Again retail get screwed.
I am out with loss
Court awarded ZERO damages....nada...not a penny. Obviously the judgment got filed on the court site earlier. It's public once it hits there.
$0.76 down 41.98%! Trading halted pending release of material news. My bet is still that the judge has ruled and it sucks!
Or MM trying to scare people to get their shares
Can go either way...
Big volume with a 33% drop so far this morning. My guess is the decision is out and it's not a good one.
Huge volume today! 1.2M
Assume leaked bd buyout or verdict for huge damages
Finished loading as the bench trial on May 11 will render a decision in next few weeks. Will see how close to the $340M damages they get from BD. So badly want to see them get a healthy payment as the Amicus briefs submitted by various legal experts like Ghosh speak volumes as to why BD and other big companies can illegally kill competition. On huge watch...
BML Investment Partners, L.P. has filed a new 13G, reporting 6.6% ownership in $RVP - https://fintel.io/so/us/rvp
Anyone have any idea what to expect. Can't BD basically tell them to piss off. Or is the amount decided by a mediator> Anyone?
RVP's appeal was the right thing to do from a business perspective.
I truly expected the SCOTUS to deny the petition for a writ of certiorari
Now the focus can be redetermination as to the amount of damages to which RVP is entitled. BD still has to pay. The only question is how much?
You were counting on that
Retractable Technologies, Inc. Announces Litigation Updates (3/21/17)
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) announced today that the U.S. Supreme Court denied its petition for a writ of certiorari to review the December 2, 2016 Fifth Circuit Court of Appeals decision in its case against Becton, Dickinson and Company (“BD”). The Fifth Circuit Court of Appeals decision had remanded the case against BD to the Eastern District of Texas for a redetermination as to the amount of damages to which Retractable is entitled. On March 17, 2017, the Eastern District of Texas set the date for the one-day bench trial for May 11, 2017 in Sherman, Texas.
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with Luer lock syringes, Luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle can also be used to aspirate fluids and collect blood. Retractable's products are distributed by various specialty and general line distributors.
For more information on Retractable, visit its website at www.retractable.com.
http://www.businesswire.com/news/home/20170321006457/en/Retractable-Technologies-Announces-Litigation-Updates
Sorry, I took the loss back in December and quit following
Could see big earnings on 3/29
Something is up, let's hope it is the pps in the next days
A million shares traded here today and not a peep. Something up?
No, the cockiness is what comes next if you wait too long to dump
What is it you interpreted as being cocky?? Because i said I timed this one perfectly??? Well I did.... You win some you lose some. I won this one, no need to be bitter
It happens sometimes. Don't get cocky
Stock may suck, but I timed this one perfectly
Green day today, that's why lol
Meh. Nothing worth talking about.
Dunno. I've taken it off my watch screen. Too many other stocks worth owning.
Added to watch list any hope here? Sorry for your loss
RTI has a possible offer on the table
The two paths forward involve accepting buyout offer or taking RTI private. RTI no longer needs the capital markets to survive but does need the shoulders of an industry leader to move their tech into the mainstream. Expected range $3.75-$5.80 per share. The December 27 meeting should be interesting.
Just my humble opinion ??
A few thoughts on the cecent ruling
What the market has completely overlooked is the fact the court affirmed the false advertising liability against BD. Due to the overturned anti-trust portion of the case, RTI looses treble damages but rest assured the affirmed liability against BD will be well north of $50million. Further, there is a special shareholders meeting on December 27, one of the items at hand, Mr. Shaw was granted to purchase 3,000,000 common shares at $2.54 per share ($7,980,000 payable to RTI). At the conclusion of the December meeting insiders will own directly and indirectly (family trusts) approx 86-88% of RTI.
Additionally RTI's Benefits Committee retained Longnecker Investment Group to reward RTI's most "loyal executives" with competitive compensation commensurate with industry standards. Competitive compensation was issued through common shares not pay. Mr. Shaw will now own and control 48.3% of the outstanding common. Shareholders rights plan extraordinar. Anyone read up on the most important patents? Expiration occurs 2020.
Mr. Shaw, distinguished members of the board, as a shareholder holding a significant position, I implore upon you to take the deal presented to RTI, settle with BD, as this presents the best path forward for all shareholders. Equally important, your life's work and passion will be in the hands of the "American healthcare industry" and allowing all to "gain access to healthcare markets that are important to the survival of emerging companies with new technologies that will save lives and offer lower prices to medical consumers and insurers.” Spend your golden years watching your dream fulfilled, not within the confines of the district court.
"The court affirmed a finding of false advertising liability against BD and remanded the case to the Eastern District of Texas for a redetermination as to the amount of damages to which RTI is entitled. RTI is evaluating the appeals court rulings and conferring with legal counsel regarding possible future action."
Retractable Technologies, Inc. Reports on Fifth Circuit's Opinion (12/06/16)
LITTLE ELM, Texas--(BUSINESS WIRE)--On Friday, December 2, the Fifth Circuit Court of Appeals overturned a district court judgment that had previously awarded Retractable Technologies, Inc. (NYSE MKT: RVP) (“RTI”) $340 million in antitrust damages from Becton, Dickinson and Company (“BD”) but affirmed a finding of false advertising liability against BD and remanded the case to the Eastern District of Texas for a redetermination as to the amount of damages to which RTI is entitled. RTI is evaluating the appeals court rulings and conferring with legal counsel regarding possible future action. Thomas Shaw, President and CEO of RTI, views the Friday decision as being “unfortunate for the American healthcare industry in that it will likely reinforce the inability of small medical products companies to gain access to healthcare markets that are important to the survival of emerging companies with new technologies that will save lives and offer lower prices to medical consumers and insurers.”
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefill syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.
For more information on Retractable, visit its website at www.vanishpoint.com.
Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.
Factors that could cause or contribute to such differences include, but are not limited to: Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; the impact of current and future Court decisions regarding current litigation; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; Retractable's ability to quickly increase capacity in response to an increase in demand; Retractable's ability to access the market; Retractable's ability to maintain or lower production costs; Retractable's ability to continue to finance research and development as well as operations and expansion of production; the impact of larger market players, specifically Becton, Dickinson and Company, in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.
Contacts
Retractable Technologies, Inc.
Douglas W. Cowan, 888-806-2626 or 972-294-1010
Vice President and Chief Financial Officer
http://www.businesswire.com/news/home/20161206006149/en/Retractable-Technologies-Reports-Circuits-Opinion
Here is the link to the decisionhttp://www.ca5.uscourts.gov/opinions/pub/14/14-41384-CV0.pdf
Probably see some sort of dead cat bounce, but I'm not waiting around to find out.
No I appreciate the info. My fault as I've been thinking I should sell when it hit $2.50. I got greedy and didn't want to take a small loss, so now I get a big one.
Thanks for the info
Five year low is 75 cents.
Sorry to share, it hit my scanner so I started looking around to see why it was down so much
Well that just made for a sucky day
Chap 11
?
CEO arrested?
Fat fingers?
Followers
|
22
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
388
|
Created
|
09/01/09
|
Type
|
Free
|
Moderators |
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety medical products for the healthcare industry in the United States and internationally. The company offers VanishPoint safety needle products to prevent needlestick injuries and reuse. Its products include 1cc tuberculin, insulin, and allergy antigen VanishPoint syringes; 0.5cc, 3cc, 5cc, and 10cc VanishPoint syringes; the VanishPoint blood collection tube holder; autodisable syringe and the VanishPoint IV safety catheter; and a small diameter tube adapter. The company's products also include Patient Safe syringe, which reduces the risk of infection resulting from IV contamination, as well as dental syringe, winged IV sets, and an autodisable syringe. It markets its products to healthcare providers, which include acute care hospitals, alternate care facilities, doctors’ offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons. The company distributes its products through general line and specialty distributors, as well as through international distributors. Retractable Technologies, Inc. was founded in 1994 and is headquartered in Little Elm, Texas.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |